The safety of APRETUDE was studied in 2 international, multicenter, double-blind trials, HPTN 083 and HPTN 084. Get more details on the risks, adverse reactions, and discontinuation rates for APRETUDE below.
See the safety profile of APRETUDE as compared with a daily oral PrEP (TDF/FTC) in cisgender men and transgender women who have sex with men and have evidence of high-risk behavior for HIV-1 infection
Review safety data for APRETUDE as compared with a daily oral PrEP (TDF/FTC) in cisgender women at risk of acquiring HIV-1
HPTN=HIV Prevention Trials Network; PrEP=pre-exposure prophylaxis.